Risk factors
uniQure (QURE) risk factors
Item 1A of every uniQure N.V. 10-K on file, and what changed from one year to the next. Readings are automated and can be wrong; check the filing for the exact wording.
- FY2025 10-K risk factors58 risks4 new1 dropped15 reworded
Clinical progress for AMT-130 faces regulatory pushback from the FDA regarding BLA submission viability. Corporate governance transitions toward the Dutch large company regime and strict Dutch legal frameworks.
Filed Mar 02, 2026 - FY2024 10-K risk factors55 risks
Gene therapy clinical trials and regulatory approvals are highly uncertain, expensive, and subject to strict compliance oversight.
Filed Feb 27, 2025